Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2306553 | 0.95 | HIF1A (0.74) | HIF1AMAPTNPC1RAB9AKMT2A | |
| Iodide SCHEMBL31325827 | 0.93 | HIF1A (0.72) | HIF1AMAPTNPC1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL29937106 | 0.93 | HIF1A (0.72) | HIF1AMAPTNPC1RAB9AKMT2A | |
| N-Benzyl-4-Methoxyaniline SCHEMBL1757104 | 0.87 | HIF1A (0.69) | HIF1AMAPTNPC1RAB9AKMT2A | |
| N-Benzyl-4-Methoxyaniline SCHEMBL5765646 | 0.86 | HIF1A (0.68) | HIF1AMAPTNPC1RAB9AKMT2A | |
| SCHEMBL1844199 | 0.85 | MAPT (0.82) | HIF1AMAPTNPC1RAB9AKMT2A | |
| SCHEMBL5669873 | 0.85 | MAPT (0.82) | HIF1AMAPTNPC1RAB9AKMT2A | |
| SCHEMBL10055019 | 0.85 | MAPT (0.82) | HIF1AMAPTNPC1RAB9AKMT2A | |
| SCHEMBL9798992 | 0.83 | FFAR1 (0.68) | HIF1ARAB9AKMT2AMEN1FFAR1 | |
| SCHEMBL11192900 | 0.83 | HIF1A (0.64) | HIF1AMAPTNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327001-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2022-04-13 | — | — | EP | disclosed |
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-08-02 | — | — | US | disclosed |
| EP-3327001-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | HIF1A 3071/4885MAPT 969/4885NPC1 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.